X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (186) 186
oncology (176) 176
index medicus (174) 174
male (119) 119
female (114) 114
aged (105) 105
middle aged (105) 105
lung neoplasms - drug therapy (85) 85
adult (81) 81
chemotherapy (80) 80
carcinoma, non-small-cell lung - drug therapy (78) 78
cancer (70) 70
lung cancer (67) 67
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
lung neoplasms - pathology (56) 56
treatment outcome (49) 49
aged, 80 and over (48) 48
carcinoma, non-small-cell lung - pathology (47) 47
care and treatment (43) 43
lung cancer, non-small cell (42) 42
mutation (42) 42
neoplasm staging (41) 41
prognosis (41) 41
lung neoplasms - genetics (40) 40
open-label (40) 40
respiratory system (38) 38
human necessities (37) 37
hygiene (37) 37
medical or veterinary science (37) 37
preparations for medical, dental, or toilet purposes (37) 37
specific therapeutic activity of chemical compounds ormedicinal preparations (36) 36
disease-free survival (35) 35
tumors (35) 35
antineoplastic agents - therapeutic use (34) 34
hematology, oncology and palliative medicine (34) 34
lung neoplasms - mortality (34) 34
therapy (34) 34
carcinoma, non-small-cell lung - genetics (33) 33
carcinoma, non-small-cell lung - mortality (31) 31
cisplatin (31) 31
expression (29) 29
cisplatin - administration & dosage (28) 28
clinical trials (28) 28
analysis (27) 27
nsclc (26) 26
survival (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
cancer therapies (25) 25
docetaxel (25) 25
kaplan-meier estimate (24) 24
survival rate (24) 24
erlotinib (23) 23
survival analysis (23) 23
cell lung-cancer (22) 22
growth-factor receptor (22) 22
patients (22) 22
research (22) 22
biomarkers (21) 21
gefitinib (21) 21
gemcitabine (21) 21
metastasis (21) 21
receptor, epidermal growth factor - genetics (21) 21
trial (21) 21
1st-line treatment (20) 20
egfr (20) 20
non-small cell lung carcinoma (20) 20
phase-iii trial (20) 20
disease progression (19) 19
pemetrexed (19) 19
antibodies, monoclonal - administration & dosage (18) 18
bevacizumab (18) 18
carcinoma (18) 18
chemistry (18) 18
non-small cell lung cancer (18) 18
non-small-cell lung cancer (18) 18
protein kinase inhibitors - therapeutic use (18) 18
adenocarcinoma (17) 17
antineoplastic agents (17) 17
carboplatin (17) 17
double-blind method (17) 17
lung neoplasms - therapy (17) 17
medicine (17) 17
metallurgy (17) 17
pulmonary/respiratory (17) 17
double-blind (16) 16
neoplasms - drug therapy (16) 16
pathology (16) 16
antineoplastic agents - adverse effects (15) 15
cancer research (15) 15
carboplatin - administration & dosage (15) 15
follow-up studies (15) 15
guanine - analogs & derivatives (15) 15
immunotherapy (15) 15
medicine & public health (15) 15
multicenter (15) 15
patient outcomes (15) 15
solid tumors (15) 15
abridged index medicus (14) 14
antimitotic agents (14) 14
biomarkers, tumor - metabolism (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (458) 458
Spanish (23) 23
French (19) 19
German (9) 9
Bulgarian (2) 2
Czech (2) 2
Norwegian (2) 2
Polish (2) 2
Portuguese (2) 2
Danish (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2490 - 2498
Journal Article
Histopathology, ISSN 0309-0167, 01/2018, Volume 72, Issue 2, pp. 270 - 284
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 958 - 967
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2040 - 2051
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
European Respiratory Journal, ISSN 0903-1936, 05/2018, Volume 51, Issue 5, pp. 1702431 - 1702431
Thromboembolic disease is fairly common in patients with lung cancer [1–3]. This incidence seems to be higher in patients with lung adenocarcinomas [4], with... 
CRIZOTINIB | RISK | MODEL | VENOUS THROMBOEMBOLISM | RESPIRATORY SYSTEM | Disease | Lung cancer | Lung diseases | Non-small cell lung carcinoma | Thromboembolism | Health risk assessment | Lymphoma | Protein-tyrosine kinase | Tumors
Journal Article